INT314618

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2010
Last Reported 2010
Negated 0
Speculated 9
Reported most in Body
Documents 2
Total Number 11
Disease Relevance 1.70
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (ZGLP1)
Anatomy Link Frequency
liver 1
spleen 1
adrenal gland 1
central nervous system 1
kidney 1
ZGLP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 1 96.84 Very High Very High Very High
Central nervous system 10 92.04 High High
cytokine 2 82.60 Quite High
adenocard 1 57.44 Quite High
agonist 54 53.72 Quite High
headache 11 5.00 Very Low Very Low Very Low
Bile 10 5.00 Very Low Very Low Very Low
Dopamine 10 5.00 Very Low Very Low Very Low
Bioavailability 3 5.00 Very Low Very Low Very Low
Parenteral administration 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Death 11 83.36 Quite High
Diabetes Mellitus 631 79.88 Quite High
Apoptosis 5 76.36 Quite High
Insulin Resistance 24 60.80 Quite High
Disease 69 50.84 Quite High
Obesity 92 48.16 Quite Low
Gastric Motility Disorder 3 27.60 Quite Low
Overnutrition 13 16.40 Low Low
Renal Disease 21 11.76 Low Low
Ocular Toxicity (including Many Sub-types) 10 11.24 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in kidney associated with central nervous system
1) Confidence 0.16 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
GLP-1 also binds to pancreatic ?
GLP-1 Binding (binds) of
2) Confidence 0.16 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.30 Pain Relevance 0.03
Some researchers have shown that both of them (GLP-1 and EX) bind and activate the pancreatic GLP-1 receptor (GLP-1R) with similar affinity and potency[13–15].
GLP-1 Binding (bind) of associated with potency
3) Confidence 0.10 Published 2010 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2883206 Disease Relevance 0.32 Pain Relevance 0.15
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in intestine associated with central nervous system
4) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in lung associated with central nervous system
5) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in adrenal gland associated with central nervous system
6) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in spleen associated with central nervous system
7) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in pancreas associated with central nervous system
8) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in testis associated with central nervous system
9) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in central nervous system associated with central nervous system
10) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
GLP-1 Spec (can) Binding (Endogenous) of in liver associated with central nervous system
11) Confidence 0.05 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox